Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
This updated edition is a great reference for anyone working in multinational product development and marketing.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 02 March 2018 | By Michael Mezher
The European Medicines Agency (EMA) on Friday announced it is urgently reviewing Biogen and AbbVie's multiple sclerosis (MS) drug Zinbryta (daclizumab) after receiving seven reports of serious inflammatory brain disorders, known as inflammatory encephalitis and meningoencephalitis, in patients taking the drug in Germany and Spain.
In response to the safety concerns, Biogen and AbbVie said they will withdraw Zinbryta from the market worldwide. EMA also says that Biogen has informed the agency that it will stop its ongoing clinical studies for the drug in the EU.
"Given the nature and complexity of the adverse events being reported, characterizing the evolving benefit/risk profile of Zinbryta will not be possible going forward given the limited number of patients being treated," the companies said in a statement, adding that Biogen will continue to work with regulators and healthcare providers to manage patients taking Zinbryta.
In its announcement, EMA said it will be contacting doctors throughout the EU with more detailed information, but in the meantime says that no new patients should start taking Zinbryta and that doctors should evaluate patients currently taking the drug and start them on an alternative therapy as soon as possible. EMA also advises patients not to stop taking Zinbryta before speaking with their doctors.
Zinbryta is currently marketed in the EU, US, Switzerland, Canada and Australia and was first approved by the US Food and Drug Administration (FDA) in May 2016 with a boxed warning for the risk of serious liver injury and immune conditions, and a risk evaluation and mitigation strategy (REMS) to restrict its distribution.
In statmenent to Focus, FDA spokesperson Jeremy Kahn said that FDA is aware of Biogen's decision to withdraw the drug from the US market and that the agency will work with the company on their withdrawal plan. EMA's announcement comes just seven months after the agency restricted the use of Zinbryta over liver safety concerns to only patients with highly active relapsing MS who have tried at least two other disease modifying treatments.
According to EMA, more than 8,000 patients have been treated with the drug in the EU, the bulk of which have been treated in Germany.
EMA, Biogen and AbbVie Statement
Regulatory Focus newsletters
All the biggest regulatory news and happenings.